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Background: The aim of this study was to characterize phenotypically enterotoxins, colonization factors (CFs) and 
the antibiotic susceptibility of enterotoxigenic Escherichia coli (ETEC) strains isolated from cases of acute diarrhea 
that occurred in Europeans traveling to resorts in Mombasa, Kenya; this information is critical for the development 
of vaccines and empirical treatment. 
Methods: Over a l-year period from 1996 to 1997, five E. coli-like colonies were obtained from each of 463 cases 
with acute diarrhea. These strains were characterized for enterotoxins using GM-1 ELISA, for CFs using a dot-blot 
assay, and for antibiotic susceptibility using antibiotic disks. 
Results: Of 164 strains characterized for ETEC phenotype, 30 (18%) expressed heat-labile toxin (LT) only, 83 (51%) 
heat-stable toxin (ST) only, and 51 (31%) both LT and ST. Analysis for CF expression demonstrated that 107 (65%) 
of the strains were positive for CFs, including CFA/IV (46%), CFA/II (35%), and CFA/I (.5%), while less than 4% 
expressed less common CFs. All ETEC strains tested were resistant to erythromycin and sensitive to ceftriaxone. 
Over one-third of the strains were resistant to sulfamethoxazole-trimethoprim or tetracycline. Six strains were 
resistant to nalidixic acid; none of these were resistant to ciprofloxacin. 
Conclusions: Cumulatively, our findings indicate that ETEC in this region comprises a highly diverse group of 
bacterial enteropathogens, and that the development of prophylactic agents against ETEC faces major challenges 
because of this diversity. 
Int J Infect Dis 2003; 7: 35-41 
INTRODUCTION 
Despite its discovery and initial characterization nearly 
30 years ago,’ enterotoxigenic Escherichia coli (ETEC) 
remains the most common cause of acute diarrhea 
among children in developing countries and travelers 
to such areas.‘-‘” Annually, an estimated 400 million 
episodes of diarrhea and up to 700 000 deaths are attri- 
buted to ETEC infections.7 The virulent nature of the 
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infection is a function of two factors, enterotoxins and 
specific adhesins called colonization factors (CFs), which 
work in concert to induce diarrhea. Both types of viru- 
lence factor are generally plasmid encoded.20*21 
CFs enable ETEC to adhere to specific receptors 
located on the surface of epithelial cells of the small 
intestine, permitting colonization.22-24 CFs commonly 
expressed by ETEC strains isolated from human disease 
include CFA/I, CFA/II, CFA/IV, CS12 (PCF0159), CS14 
(PCF0166), and CS17. Several other CFs have been 
identified, including CS7, CS8 (CFA/III), CSlO (2230) 
CSll (PCF0148), CS13 (PCF09), CS18 (PCF020), 
CS19, CS20, and CS21 (Longus). CFA/II strains can 
express CSl +CS3 and CS2+CS3 or CS3 alone, and 
CFA/IV strains can express CS4+CS6 or CS5+ CS6 or 
CS6 only. 
ETEC strains also express one or both of two 
enterotoxins: a heat-stable toxin (ST), and a heat-labile 
toxin (LT), which act at the epithelial surface of the 
small intestine.25x26 LT is an immunogenic protein that 
is structurally, functionally and antigenically related to 
cholera toxin.27 ST is a non-immunogenic protein of 
18-20 amino acids that is functionally and structurally 
related to the mammalian protein guanylin.28 Expression 
of LT or ST initiates a sequence of events resulting in 
the activation of adenylate cyclase or guanylate cyclase 
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and increased levels of CAMP or cGMP, respectively.25J6 
AS a result, disturbances in electrolyte balance take 
place, with the resulting fluid secretion causing watery 
diarrhea. 
While the diarrhea caused by ETEC is usually of 
short duration and self-limiting, it is a significant cause 
of morbidity and incapacity among Western travelers 
to endemic regions, and of mortality among young 
children resident in these regions. While antibiotics are 
often used to alleviate the symptoms of acute infection, 
limited and often outdated information, compounded by 
increasing drug resistance, has made empirical treat- 
ment difficult. Several prophylactic and treatment drug 
regimens have been described for ETEC diarrhea1 
disease,29,“0 with quinolones being the current drugs of 
choice for both prophylaxis and treatment. However, 
the use of quinolones in the pediatric population 
remains controversial. Therefore, other methods, in- 
cluding vaccine development, have been aggressively 
pursued for the control of ETEC infections. To develop 
a vaccine offering the broadest protective potential, 
and to assess the extent of antibiotic resistance, the 
characterization of representative ETEC strains from 
different geographic regions is a necessity. 
Previous epidemiologic surveys conducted in com- 
munity-based settings within distinct geographic areas 
of South America, Asia and the Middle East endemic 
for ETEC have shown substantial variation in the 
distribution of ETEC toxin types and CFs. Expression of 
ST and LT varied from 24% to 65%, and from 21% to 
50%, respectively, while the expression of LTST varied 
from 9% to 27%.5J7,31 These studies also reported that 
up to 50% of ETEC strains apparently did not express 
any CFs, suggesting a potential protective gap in current 
vaccine prototypes. However, little information is avail- 
able on toxin and CF phenotype or antibiotic resistance 
of ETEC strains isolated from travelers to Africa, 
another region endemic for ETEC. 19,32 Therefore, in the 
present study, we report the characterization of ETEC 
strains obtained from cases of diarrhea that occurred in 
European tourists visiting resorts in Mombasa, Kenya. 
MATERIALS AND METHODS 
Bacterial strains 
As part of a study to determine the prevalence of 
diarrhea in travelers, Europeans vacationing in 
Mombasa, Kenya between September 1996 and August 
1997 were asked to come to a local clinic for evaluation 
should they develop diarrhea during their stay.33 After 
the patient was evaluated in the clinic, they were asked 
to provide a stool specimen for analysis. A sample 
of stool was streaked onto bacterial culture media, 
including MacConkey’s and blood agar plates. From 
these plates, five lactose-positive E. c&-like colonies 
were selected and individually stored at -70°C in brain 
heart infusion broth supplemented with 15% glycerol. 
At regular intervals, these lactose-positive isolates were 
shipped to the Naval Medical Research Unit (3) Cairo, 
Egypt for ETEC testing, using a GM1 ELISA assay to 
detect either ST or LT, as previously described.34*35 
For each set of five isolates tested, if any were 
positive for an enterotoxin, the patient was said to have 
had ETEC-associated diarrhea, and the toxin-positive 
isolates were tested for CF expression, using monoclonal 
antibodies against CFA/I, CSl, CS2, CS3, CS4, CS5, CS6, 
CS7, CS8, CS12, CS14, and CS17.36-38 The following 
reference strains were used as controls for enterotoxin 
and CFA expression: 286C2 (LT), ST64111 (ST), 258909-3 
(LTST and CFA/I), El392 (CSl), E278485/2 (CS2), 
VM73494 (CS3), E11881/9 (CS4), E17018A (CS5), 
VM75688 (CS6), E29101A (CS7), E34420A (CS8), 
E350ClA (CS12), E3476A (CS14), E20738A (CS17), 
and HS4, a commensal strain isolated from a human 
volunteer. If all the isolates from a given case of diarrhea 
had the same toxin and CF phenotype, then one isolate 
was selected as representative. In two diarrhea cases, 
ETEC isolates were found to be expressing different 
combinations of toxins. From these cases of mixed ETEC 
infection, two isolates representative of the different 
toxin and CF profiles identified were selected. In total, 
164 ETEC strains from 162 diarrhea1 cases were charac- 
terized. 
Antibiotic susceptibility testing 
Antimicrobial susceptibility testing of the ETEC isolates 
for ceftriaxone, gentamicin, erythromycin, tetracycline, 
nalidixic acid, ciprofloxacin and trimethoprim- 
sulfamethoxazole was performed, using the disk diffusion 
method.39 Those strains found to be resistant to nalidixic 
acid were also tested for susceptibility to ciprofloxacin. 
NCCLS guidelines were used to determine whether 
an isolate was sensitive, intermediate-sensitive, or 
resistant.40 For analysis, isolates with an intermediate 
zone of resistance to an antibiotic were considered to be 
resistant to that drug. 
Statistical analysis 
Data analyses were performed using Pearson’s chi- 
square test programmed into the spreadsheet module of 
AppleWorks (Apple Computer, Cupertino, California, 
USA). 
RESULTS 
Over a l-year period, 463 cases of diarrhea were 
reported from which a stool specimen was processed 
for pathogens. ETEC was identified as the pathogen in 
162 of these cases. From the 162 cases of ETEC- 
mediated diarrhea, 164 isolates were selected as 
representative strains. Eighteen per cent (30064) of 
the strains expressed LT only, 51% (83/164) ST only, 
and 31% (51/164) both LT and ST. Sixty-five per cent 
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(107/164) of these strains expressed a known CF (Figure 
1). The remaining 35% (57/164) of the strains were 
phenotypically negative for a CF. Among the CF- 
positive isolates, 46% (491107) were CFA/IV positive, 
35% (37/107) CFA/II positive, and 5% (5/107) CFA/I 
positive, while less than 4% expressed CS7 (3/107), CS8 
(4/107), CS12 (2/107), CS14 (4/107), or CS17 (3/107). 
Of the CFA/IV-positive isolates, 90% (44/49) expressed 
CS6 only, 6% (3/49) CS4+CS6, and 4% (2149) 
CS5 +CS6. Of the CFA/II-positive isolates, 5% (2/37) 
expressed CS3 only, 70% (26/37) CSl+CS3, and 24% 
(9/37) CS2+CS3. All four ETEC strains that were 
positive for CS8 also co-expressed CS6. 
A higher percentage of the ST-only and LT+ST 
ETEC strains expressed known CFs (70%, 58/83, and 
71%) 36/51, respectively) as compared to LT-only strains 
(43%, 13/30). A mong 91 strains that expressed CFA/I, 
(A) LT only (n=30/164, 18%) 
CFAIII, or CFA/IV, 87 of 91 (96%) strains expressed ST 
either as the sole toxin or in combination with LT (Table 
l), whereas 4 of 91 (4%) expressed LT only, and CS6 
was the only antigen detected. Fifty-seven of the 164 
(35%) ETEC strains did not express any detectable 
CFs: 17 expressed LT only, 25 expressed ST only, and 15 
expressed both LT and ST. 
One hundred and fifty-seven of the 164 (96%) 
ETEC strains were tested for antibiotic resistance. No 
statistically significant correlation between antibiotic 
resistance pattern and enterotoxin or CF expressed 
could be discerned (all P>O.l). All strains were resistant 
to erythromycin and sensitive to ceftriaxone or cipro- 
floxacin. Sixty-two strains (39%) were resistant to 
trimethoprim-sulfamethoxazole, and 66 (42%) were 
resistant to tetracycline, while 38 (24%) strains were 
resistant to both of these antibiotics in addition to 
(C) LTST (n=51/164, 31%) 
CF negativ 
57% 
CS6 _/ 
24% 
I 
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CFNI 
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Figure 1. Distribution of the expressed coli surface (CS) antigens in relation to toxin phenotype: LT (A), ST (B), and LT+ST (C). 
(D) demonstrates the distribution of the expressed CS for all ETEC strains isolated from travelers suffering from aqueous diarrhea. 
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Table 1. Phenotypic profile of ETEC strains in relation to rCTB- and CF-based vaccine comoonents. 
Colonization factors LT (“7) 
CFA/I and CSI-CS6 4 (2.4) 
CS17, CS.8 and CS17 9 (5.5) 
CSl2 and CS14 - 
Negative CFs 17 (10.4) 
Total (%) 30 (18.3) 
LTST (%) 
34 (20.7) 
2 (1.2) 
15 (9.1) 
51 (31.1) 
ST (%) 
53 (32.3) 
1 (0.6) 
4 (2.4) 
25 (15.2) 
83 (50.6) 
Total (%) 
91 (55.5) 
10 (6.1) 
6 (3.7) 
57 (34.8) 
164 (100.0) 
erythromycin. A single strain (<l%) was resistant to 
gentamicin, while six strains (4%) were resistant to 
nalidixic acid. All of the nalidixic acid-resistant strains 
were susceptible to ciprofloxacin. Five strains (3%) were 
resistant to four antibiotics. Four of these were resistant 
to erythromycin, nalidixic acid, trimethoprim-sulfa- 
methoxazole, and tetracycline. The other strain was 
resistant to erythromycin, gentamicin, nalidixic acid, and 
tetracycline. 
DISCUSSION 
Past phenotypic characterization studies of ETEC 
isolated from Africa have focused on the analysis of 
enterotoxin, but not CF, expression.2,9J0J7 This limitation 
makes it difficult to assess the protective potential of 
existing vaccine prototypes and to decide which com- 
ponents to add to future vaccines. Furthermore, data in 
the literature are limited with regard to the antibiotic 
susceptibilities of ETEC pathogens. In this study, we 
have phenotypically characterized ETEC strains from 
defined cases of acute diarrhea in Western travelers over 
a l-year period with respect to enterotoxin production, 
CF expression, and antibiotic susceptibility. 
Previous studies have indicated that many anti- 
biotics commonly prescribed for acute diarrhea are in- 
effective, due to the high prevalence of multiresistant E. 
c~li.~~J~,~’ We have demonstrated that ETEC strains 
from Egypt are routinely resistant to ampicillin, strepto- 
mycin, and chloramphenicol (David et al, unpublished 
data). Some investigators have reported an association 
between multiresistance and enterotoxin phenotype. 
DeBoy et al found that multiresistance occurred 
more often in ST-producing strains,32 while Turner et al 
observed that such resistance was more common in LT- 
producing strains.42 In the current study, we were unable 
to discern any relationship between drug resistance and 
the type of toxin produced. 
The pattern of enterotoxin expression worldwide 
is such that ST-only ETEC strains are more common 
than either LT-only or LTST strains.43 The phenotypic 
distribution of our ETEC strains is in agreement with 
this global trend. However, regional variations in ETEC 
enterotoxin phenotype abound, even within restricted 
geographic areas. 2&44 While a study in rural Egypt found 
that LT-only strains comprised 60% of all ETEC strains, 
and ST-only strains comprised 36%, a subsequent study 
found ST-only strains to outnumber LT-only strains by 
nearly two to one. 2*17 A similar paradox was seen in 
studies conducted on deployed Western forces during 
the Gulf War. Among US troops, nearly half of the 
ETEC strains isolated expressed both LT and ST, 
and of the balance, 39% expressed ST only, and 17% 
expressed LT only.” In contrast, 73% of the ETEC 
strains isolated from neighboring UK troops expressed 
ST only.‘l 
Similarly, surveys of ETEC strains from different 
regions have shown a wide variation in the percentage 
of strains expressing CFs. The current study, with 65 % of 
the strains expressing a known CF, was at the higher end 
of reports from the literature, which give values ranging 
from approximately 20% to 75% .3J,12,17.19,44,45 The 
predominant CF that we identified was CFAIIV, with 
CS6 alone as the principal antigen detected, followed by 
CFA/II, with CS3+ CSl the most common combination. 
ETEC strains expressing CFA/I or other CF antigens 
were found in only a few cases in this study. This 
distribution is similar to our previous findings from a 
community-based study in Northern Africa,17 but differs 
from that seen during the Gulf War, in which Wolf et al” 
identified a higher percentage of ETEC strains that 
expressed CFA/II, compared to those that expressed 
CFA/IV. While some studies have found antigens such as 
CS8, CS12, CS14 or CS17 comprising a substantial 
percentage of the CFs detected, we found that they 
constituted only a small proportion of the total 
CFs.23.24,43 Interestingly, we found that CS8 was always 
co-expressed with CS6, a rarely reported combination of 
antigens. 
Previous studies have found that CF expression 
is more likely to be found among ST-producing 
strains 23,24,43.44,46 while LT-positive strains are more 
likely ;o be CF negative, as a result of either the loss of 
a plasmid encoding for a CF, or the expression of a less 
common or, as yet unidentified, CF.12,47 In this study, 
a high percentage (53%) of the ST-associated ETEC 
strains expressed the most common CFs, namely CFA/I 
and CSl-6. Common epitopes between members of the 
CFA/I family, namely CSl, CS2, CS4, CS14, CS17, and 
CS19, have been demonstrated.24,4x Such cross-reactions 
may induce an antibody response, not only to homo- 
logous but also to heterologous CFS.~~,“’ Furthermore, a 
protective immunity to ETEC strains (LT positive), 
in particular strains expressing CS7 and CS17, has 
been demonstrated to be age associated in primed 
children.1y*51 Ten per cent of the isolated ETEC strains 
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were LT or ST associated, and expressed less common 
CFs. The remaining 35% of the ETEC strains (10% LT 
only and 25% ST associated) did not express known 
CFs, and most of these expressed LT, corroborating the 
earlier studies. We have examined some of the apparently 
CF-negative ETEC strains, and found that many appear 
to express previously undescribed CFS~~ (Khalil et al, 
unpublished data). 
In the context of the development and testing of 
candidate anti-ETEC vaccines, our findings indicate that 
the formulation of a broadly protective vaccine against 
ETEC poses major challenges because of the strain 
diversity. As anti-LT and CF immunity both play a 
role in protection against ETEC disease,s2,s3 the current 
prototype ETEC vaccine is designed to reflect this 
observation. The toxoid component of the prototype 
ETEC vaccine, recombinant cholera toxin ‘B’ subunit 
(rCTB), induces a considerable anti-LT immunity that 
encompasses LT-positive strains, but leaves ST-only 
strains untargeted. To circumvent this protective gap, 
CFA/I and CSl-6 are included in the vaccine formu- 
lation.54-s6 Following this line of reasoning, our findings 
suggest that such an ETEC vaccine will be at least 75% 
protective against regional ETEC isolates (Table 1). The 
remaining 25% of the ETEC strains are ST associated 
and CF negative. These strains need further charac- 
terization with the use of antibody probes for the 
detection of the less common CFs, including CSlO, CSll, 
CS13, CS18, CS19, CS20, and CS21, to determine the 
incidence of such CFs in regional endemic areas for 
vaccine purposes. Thus, phenotypic characterization of 
representative ETEC strains from diverse geographic 
regions endemic for ETEC, particularly for CFs, remains 
a critical prerequisite for the assessment of the pro- 
tective potential of current prototypes and for the 
design of future vaccines. For this reason alone, the 
identification and characterization of new CFs is critical 
to enhance the potential protective scope of prototype 
anti-ETEC vaccines and to develop tools needed to 
determine the relative prevalence of different CFs on a 
regional basis. 
Our findings show that, phenotypically, ETEC is a 
complex and diverse pathogen, corroborating results 
reported elsewhere. ‘2.14.17,s7 This apparent complexity 
poses major challenges for prophylactic and preventive 
measures. Among the diversity, we were still able to 
detect combinations of enterotoxin and CF that 
occurred more frequently, most notably LT-only strains 
with CS8+CS6, CS7, or CS17, LTST strains with 
CFA/II, CFA/IV, or CS14, and ST-only strains with 
CFA/I, CFA/II, CFA/IV, or CS12. The potential 
adaptive advantages, if any, of these preferred com- 
binations are unknown. Nevertheless, the phenotypic 
diversity of ETEC makes it clear that an effective and 
broadly protective vaccine must incorporate multiple 
protective antigens and perhaps also be designed to 
take into account specific regional phenotypic varia- 
tions. 
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